New criteria set for flexible ICER threshold evaluations
By Lee, Tak-Sun | translator Kang, Shin-Kook
24.08.20 05:58:46
°¡³ª´Ù¶ó
0
Reviewed through DREC review on the 8th¡¦Includes improvements to the Risk-Sharing Agreement scheme
The National Health Insurance Review and Assessment Service (HIRA) established new criteria for drugs that apply flexible ICER (incremental cost-effectiveness ratio) thresholds during the Drug Reimbursement Evaluation Committee (DREC) meeting that was held on the 8th.
The previous criteria only stipulated that a flexible ICER threshold could be applied, but specifics were established. this time. In February, DREC recognized reimbursement adequate for the breast and stomach cancer drug Enhertu (trastuzumab deruxtecan, Daiichi Sankyo Korea) by flexibly applying the ICER threshold.
On the 8th, HIRA disclosed the "Criteria for detailed evaluation of drugs subject to negotiation, suc
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)